July 2018
Volume 59, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2018
Management of Diabetic macular oedema with Intravitreal Ranibizumab -Outcome after three years
Author Affiliations & Notes
  • Hemalatha Kolli
    Ophtholmology, BMEC, Birmingham, United Kingdom
  • Monali Chakrabarti
    Ophtholmology, BMEC, Birmingham, United Kingdom
  • Dipali Aralikatti
    Ophtholmology, BMEC, Birmingham, United Kingdom
  • Mostafa El Gammal
    Ophtholmology, BMEC, Birmingham, United Kingdom
  • Randhir Chavan
    Ophtholmology, BMEC, Birmingham, United Kingdom
  • Samer Elsherbiny
    Ophtholmology, BMEC, Birmingham, United Kingdom
  • Arijit Mitra
    Ophtholmology, BMEC, Birmingham, United Kingdom
  • Peck-Lin Lip
    Ophtholmology, BMEC, Birmingham, United Kingdom
  • Bushra Mushatq
    Ophtholmology, BMEC, Birmingham, United Kingdom
  • Footnotes
    Commercial Relationships   Hemalatha Kolli, None; Monali Chakrabarti, None; Dipali Aralikatti, None; Mostafa El Gammal, None; Randhir Chavan, None; Samer Elsherbiny, None; Arijit Mitra, None; Peck-Lin Lip, None; Bushra Mushatq, None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4823. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hemalatha Kolli, Monali Chakrabarti, Dipali Aralikatti, Mostafa El Gammal, Randhir Chavan, Samer Elsherbiny, Arijit Mitra, Peck-Lin Lip, Bushra Mushatq; Management of Diabetic macular oedema with Intravitreal Ranibizumab -Outcome after three years. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4823. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To report 3 year outcome data following management of Diabetic Macular Oedema with Ranibizumab

Methods : Inclusion criteria
All patients with DMO who have completed 36 months follow up after commencing loading dose of Ranibizumab

Data Collection
Retrospective notes review of Medisoft entries and CDA
Patient demographics, visual acuity(VA),and Central retinal thickness (CRT) at baseline, after loading dose,12, 24 and 36 months

Treatment for DMO prior to Ranibizumab
Bevazuzimab 30
Macular laser 64
IVTA 17

Other interventional treatments for DMO
Triamcinolone 5
Ozurdex 4
Bevazuzimab 13
Iluvien 15
Macular laser 30

Results : The study included116 Patient,148 eyes.
There were 51 males and 65 females
The mean age was 66 years, range 29-88 years.
Bilateral 32 eyes
Right : Left,76 : 72
12 patients had Type 1 DM while 104 had Type 2 DM.
The mean duration of diabetes was16 years, range 1-30years.

Total number of injections
Year 1 –mean 5 (3-12)
Year 2 –mean 1.8 (0-6)
Year 3 – mean 1.5 (0-7)

Surgical intervention
Cataract surgery with IOL -30
PPV -1
PPV+Phaco+IOL+Peel+Endolaser -1
PPV+ERM peel+IVTA -1

The visual acuity evaluation at 3 year review
64 eyes (43%) showed improvement,
24 eyes (16.2% gaining more than15L)
84 eyes (57%) had some progression
15 eyes (10% had>15L deterioration

Conclusions : Ranibizumab has shown to improve VA in 43% of patients treated for DMO over 3 years
10% of patients had deterioration of VA over a three year period
There was progressive decrease in CRT over a three year period
Ranibizumab is well tolerated with low risk of complications (<1%)

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×